Transcriptional Regulatory Factor X6 (Rfx6) Increases Gastric Inhibitory Polypeptide (GIP) Expression in Enteroendocrine K-cells and Is Involved in GIP Hypersecretion in High Fat Diet-induced Obesity*

Kazuyo Suzuki, Norio Harada, Shunsuke Yamane, Yasuhiro Nakamura, Kazuki Sasaki, Daniela Nasteska, Erina Joo, Kimitaka Shibue, Takanari Harada, Akihiro Hamasaki, Kentaro Toyoda, Kazuaki Nagashima, and Nobuya Inagaki

From the Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

Received for publication, September 27, 2012, and in revised form, November 28, 2012. Published, JBC Papers in Press, November 28, 2012, DOI 10.1074/jbc.M112.423137

**Background:** Gastric inhibitory polypeptide (GIP) secreted from enteroendocrine K-cells potentiates insulin secretion and induces energy accumulation into adipose tissue. Plasma GIP levels are reported to be increased in the obese state. However, the molecular mechanisms of GIP secretion from enteroendocrine K-cells in response to nutrient ingestion are unclear, primarily due to difficulties in separating K-cells from other intestinal epithelial cells. In this study, GIP-GFP knock-in mice that enable us to visualize K-cells by enhanced GFP were established. Microarray analysis of isolated K-cells from these mice revealed that transcriptional regulatory factor X6 (Rfx6) is expressed exclusively in K-cells. In vitro experiments using the mouse intestinal cell line STC-1 showed that knockdown of Rfx6 decreased mRNA expression, cellular content, and secretion of GIP. Rfx6 bound to the region in the gip promoter that regulates gip promoter activity, and overexpression of Rfx6 increased GIP mRNA expression. HFD induced obesity and GIP hypersecretion in GIP-GFP heterozygous mice in vivo. Immunohistochemical and flow cytometry analysis showed no significant difference in K-cell number between control fat diet-fed (CFD) and HFD-fed mice. However, GIP content in the upper small intestine and GIP mRNA expression in K-cells were significantly increased in HFD-fed mice compared with those in CFD-fed mice. Furthermore, expression levels of Rfx6 mRNA were increased in K-cells of HFD-fed mice. These results suggest that Rfx6 increases GIP expression and content in K-cells and is involved in GIP hypersecretion in HFD-induced obesity.

**Results:** Transcriptional Rfx6 is expressed in K-cells and increases GIP expression. Rfx6 expression is up-regulated in K-cells of obese mice.

**Conclusion:** Rfx6 plays critical roles in GIP expression and hypersecretion in obesity.

**Significance:** Gene analysis of K-cells isolated from GIP-GFP knock-in mice enabled identification of Rfx6.

Gastric inhibitory polypeptide (GIP) is an incretin released from enteroendocrine K-cells in response to nutrient ingestion. GIP potentiates glucose-stimulated insulin secretion and induces energy accumulation into adipose tissue, resulting in obesity. Plasma GIP levels are reported to be increased in the obese state. However, the molecular mechanisms of GIP secretion from other intestinal epithelial cells remain unclear, primarily due to difficulties in separating K-cells from other intestinal epithelial cells in vivo. In this study, GIP-GFP knock-in mice that enable us to visualize K-cells by enhanced GFP were established. Microarray analysis of isolated K-cells from these mice revealed that transcriptional regulatory factor X6 (Rfx6) is expressed exclusively in K-cells. In vitro experiments using the mouse intestinal cell line STC-1 showed that knockdown of Rfx6 decreased mRNA expression, cellular content, and secretion of GIP. Rfx6 bound to the region in the gip promoter that regulates gip promoter activity, and overexpression of Rfx6 increased GIP mRNA expression. HFD induced obesity and GIP hypersecretion in GIP-GFP heterozygous mice in vivo. Immunohistochemical and flow cytometry analysis showed no significant difference in K-cell number between control fat diet-fed (CFD) and HFD-fed mice. However, GIP content in the upper small intestine and GIP mRNA expression in K-cells were significantly increased in HFD-fed mice compared with those in CFD-fed mice. Furthermore, expression levels of Rfx6 mRNA were increased in K-cells of HFD-fed mice. These results suggest that Rfx6 increases GIP expression and content in K-cells and is involved in GIP hypersecretion in HFD-induced obesity.

Obesity leads to insulin resistance characterized by fasting hyperinsulinemia and excessive insulin secretion to maintain euglycemia after meal ingestion. Obesity is an important risk factor in progression to type 2 diabetes mellitus as well as cardiovascular disease, and reduction of obesity can normalize hyperinsulinemia and impede the progression of diabetes and arteriosclerosis.

Gastric inhibitory polypeptide, also called glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) are the incretins, peptide hormones released from the gastrointestinal tract into circulation in response to meal ingestion that potentiate glucose-stimulated insulin secretion. GIP is secreted from enteroendocrine K-cells located in the duodenum and upper small intestine; GLP-1 is secreted from enteroendocrine L-cells located in the lower small intestine and colon. GIP binds to the GIP receptor (GIPR) on the surface of pancreatic ß-cells, adipose tissue, and osteoblasts, and it stimulates insulin secretion, fat accumulation, and bone formation, respectively, by increasing the level of intracellular adenosine 3',5'-monophosphate (cAMP).

It was reported previously that GIP-R deficient mice exhibit insufficient compensatory insulin secretion upon high fat loading, suggesting that GIP plays a critical role in maintaining blood glucose levels by hypersecretion of insulin in diet-induced obesity. We also reported that sensitivity of GIP to GIP in ß-cells is increased in high fat diet (HFD)-induced obese mice. In addition, GIP is expressed in adipose tissue and increases glucose and triglyceride uptake in fat cells. Thus, GIP has both direct and indirect effects on the accumulation of energy into adipose tissue. Some studies report that GIP secretion is increased in obesity and that pancreatic and duodenal homeobox 1 (Pdx1), which is known to be

*This work was supported by scientific research grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, the Ministry of Health, Labor, and Welfare, Japan, and scientific research grants from the Japan Diabetes Foundation.

1 To whom correspondence should be addressed. Tel.: 81-75-751-3562; Fax: 81-75-751-6601; E-mail: inagaki@metab.kuhp.kyoto-u.ac.jp.
Rfx6 Increases GIP mRNA Expression in K-cells

an important transcription factor in pancreatic development and pancreatic β-cell maturation (17), has a critical role in GIP production in K-cells (18, 19). However, the mechanisms involved in GIP hypersecretion from K-cells in obesity remain unclear due to difficulties in separating these cells from other intestinal epithelial cells in vivo.

In this study, we investigated expression of various genes in K-cells by using GIP-GFP knock-in (GIP-GFP) mice in which K-cells can be visualized by EGFP fluorescence. We found that regulatory factor X6 (Rfx6) is expressed exclusively in K-cells of the upper small intestine and is involved in GIP mRNA expression in the mouse small intestinal cell line STC-1. Furthermore, expression of Rfx6 as well as Pdx1 was found to be increased in K-cells of HFD-induced obese mice. Thus, GIP expression is stimulated by both Rfx6 and Pdx1, suggesting that these transcription factors play an important role in both GIP expression and GIP hypersecretion in HFD-induced obesity.

EXPERIMENTAL PROCEDURES

Animals—We designed targeting vector constructs as short-EGFP-poly(A)-loxP-Neo-loxP-long cassettes using mouse B6N BAC clone (identification numbers RP23-31E4 and RP23-383D10). A diphtheria toxin A expression cassette for negative selection was attached to the 3’ end of the gip sequence in the targeting vector. Next, the targeting vector was injected into embryonic stem cells from C57BL/6 mice, and a Neo resistance strain was established. The ES cells positive for the knock-in gene were selected by Southern blot analysis. The established ES cells were then injected into the blastocyst to obtain chimeric mice. Finally, we generated hetero-mutant mice by mating chimeric mice with wild-type C57BL/6 mice. The mice were housed in an air-controlled (temperature 25 °C) room and procedures were approved by the Animal Care Committee of Kyoto University.

GIP-GFP heterozygous mice (7 weeks of age) were fed control fat chow (CFD; 10% fat, 20% protein, and 70% carbohydrate by energy) or high fat chow (HFD; 60% fat, 20% protein, and 20% carbohydrate by energy) (Research Diets Inc., New Brunswick, NJ) for 8 weeks. Food intake, water intake, and body weight were measured.

Immunohistochemistry—Mouse upper small intestine samples were fixed in Bouin’s solution and transferred into 70% ethanol before processing through paraffin. Rehydrated paraffin sections were incubated overnight at 4 °C with primary mouse anti-GFP antibody (sc-9996, 1:100, Santa Cruz Biotechnology) and rabbit anti-GIP antibody (T-4053, 1:100, Peninsula Laboratories, Inc., San Carlos, CA). Intestine sections and STC-1 cells (kindly provided by Prof. Hanahan, University of California, San Francisco) were embedded by Tissue-Tek O.C.T. compound 4583 (Sakura Fine Technical Co. Ltd., Tokyo, Japan) and immediately frozen in liquid nitrogen. Frozen sections (10 μm) on slides were air-dried and fixed in acetone for 5 min. Slides were then washed in phosphate-buffered saline (PBS) and blocked for 15 min in 3% BSA. They were incubated overnight at 4 °C with primary antibody (mouse anti-GFP antibody (1:100, kindly provided by Merck Millipore) and goat anti-Rfx6 antibody (ABD28, 1:100, Merck). The sections were incubated for 1 h at room temperature with secondary antibody. Images were taken using a fluorescent microscopy with a BX-800 system (KEYENCE Corp., Osaka, Japan) and confocal microscopy with an LSM510 META system (Carl Zeiss Co., Ltd., Jena, Germany).

Fifty representative mucous membranes from each slide were randomly selected, and their mean length and GFP-positive cells were quantified using fluorescent microscopy images. To count the GFP-positive cells, we distinguished the mucous membrane as villus, upper crypt, or lower crypt.

Isolation of K-cells from Mouse Intestinal Epithelium—Mouse upper small intestine was removed and washed by PBS. The intestine was cut into several round pieces and tied on one side with a thread. The pouch-like intestine was injected with Hanks’ balanced salt solution containing 0.5 mg/ml collagenase, clamped, and incubated with CO2 at 37 °C for 10 min in Krebs-Ringer bicarbonate buffer (KRBB: 120 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.4 mM CaCl2, 20 mM NaHCO3). The digested intestinal epithelium was collected into the tube filled with Roswell Park Memorial Institute (RPMI) medium and rinsed twice. The intestinal epithelium was cultured in a humidified incubator (95% air and 5% CO2) at 37 °C for 1 h. Afterward, it was centrifuged at 180 × g for 5 min, resuspended in PBS twice, and filtered with a cell strainer (352340, Falcon cell strainer, BD Biosciences). GFP-positive cells in the intestinal epithelium were analyzed using BD FACS Aria™ flow cytometer (BD Biosciences). Sorted cells were collected into vials containing medium at a rate of 2000 cells/tube.

Total RNA was extracted with PicoPure RNA isolation kit (Applied Biosystems, Inc., Alameda, CA) from sorted cells of GIP-GFP mouse intestinal epithelium and treated with DNase (Qiagen Inc., Valencia, CA). Microarray analysis was performed using GeneChip Mouse Genome 430 2.0 Array (Affymetrix Inc., Fremont, CA).

Glucose Tolerance Test (OGTT) and GIP Assay—After a 16-h fasting period, OGTTs (1 g/kg body weight) were performed. Blood samples were taken at the indicated times (0, 15, 30, 60, and 120 min after glucose loading), and blood glucose levels, plasma insulin levels, and plasma total GIP concentrations were measured. Blood glucose levels were determined by the glucose oxidase method (Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan). Plasma insulin levels were determined using enzyme immunoassay (Shibayagi, Gumma, Japan). Plasma total GIP levels were determined using an ELISA kit (Merck Millipore).

For measurement of GIP content in the mouse upper small intestine, the mice were killed at 15 weeks of age after 8 weeks of CFD or HFD feeding. The intestine was rapidly removed and washed in PBS. After measuring the weight, samples were extracted with 5 ml/g acid ethanol, and GIP levels were measured (15).

Quantitative RT-PCR—Complementary DNA (cDNA) was prepared by reverse transcriptase (Invitrogen) with an oligo(dT) primer (Invitrogen). Messenger RNA (mRNA) levels were measured by quantitative RT-PCR using ABI PRISM 7000 Sequence Detection System (Applied Biosystems Inc.). PCR analyses were carried out using the oligonucleotide primers. SYBR Green PCR master mix (Applied Biosystems Inc.) was prepared for PCR run. Thermal cycling conditions were dena-
Rfx6 Increases GIP mRNA Expression in K-cells

To determine incretin content, STC-1 cells cultured on 12-well dishes (48 h after transfection) were washed with PBS and homogenized in 0.5 ml of 0.1 N HCl and extracted at RT for 10 min, after which the supernatant was collected and centrifuged at 3000 × g for 10 min. Incretin and protein levels were measured by ELISA (GIP and GLP-1) and Bradford reagent (Bio-Rad), respectively.

Yeast One-hybrid Assay—Yeast one-hybrid assays were performed using the Matchmaker Gold Yeast One-hybrid Library Screening System (Clontech) according to the manufacturer's protocol. The gip promoter fragments shown in Fig. 4A were inserted separately upstream of the aureobasidin A resistance gene on the pAbAi vector, and Rfx6 cDNA was inserted downstream of GAL4-activating domain (GAL4AD) on the pGADT7 activating domain vector. The interactions between gip promoter fragments and Rfx6-GAL4AD protein were assayed using the aureobasidin A resistance gene reporter system. First, Saccharomyces cerevisiae Y1HGold (MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4Δ, gal80Δ, met-MEL1) was transformed by gip promoter fragment-inserted pAbAi plasmid (pAbAi-fragments a, b, c, and d), and spread on the synthetic medium with dextrose (SD) (without uracil) and incubated for 1 week at 30 °C. Obtained yeast was transformed by Rfx6 cDNA-inserted pGADT7 activating domain plasmid (pGADT7-Rfx6), spread on the SD (without tryptophan) medium, and then incubated for 1 week at 30 °C. Interaction between gip promoter fragment and Rfx6-GAL4AD protein could be detected, and the transformant was grown on SD (without tryptophan) medium containing 600 ng/ml aureobasidin A.

GIP Promoter Activity—1 × 10⁶ STC-1 cells were cotransfected with pGL4.19 luciferase reporter plasmid expressing five different lengths of the gip promoter gene (Fig. 4C) and pGL4.73 Renilla luciferase reporter plasmid. 48 h after transfection, luciferase and Renilla activities were assayed according to the manufacturer's protocol (Promega Corp., Madison, WI) using a GloMax 20/20n luminometer (Promega). Firefly luciferase activity was normalized to Renilla luciferase expression and is presented as fold increase in relative light units over samples transfected with pGL4.19. All samples were analyzed in duplicate.

Analysis—The results are given as means ± S.E. (S.E., n = number of mice). Statistical significance was determined using paired and unpaired Student’s t test and analysis of variance. p ≤ 0.05 was considered significant.

RESULTS

Visualization and Isolation of K-cells Using GIP-GFP Mice—GIP-GFP mice were generated for the purpose of visualizing enteroendocrine K-cells (Fig. 1A). The mouse gip gene is composed of six exons. The targeting vector for GIP-GFP mice was designed so that EGFP cDNA was fused with exon 3 in the gip gene. Prepro-GIP consists of 144 amino acids (Fig. 1B), and PC1/3 and PC2 cleave prepro-GIP, generating GIP(1–42) and GIP(1–30), respectively. In GIP-GFP mice, the fusion protein retains the signal peptide, but it does not have the GIP(1–42) sequence nor the PC1/3 and PC2 cleavage sites. Accordingly, GIP-GFP mice express GIP signal peptide-GFP fusion protein.
(280 amino acids). GFP fluorescence was observed in the small intestine of GIP-GFP heterozygous mice (Fig. 1C) and GIP-GFP homozygous mice (data not shown).

Immunohistochemical analysis was performed to assess localization of GFP-expressing cells and GIP-expressing cells using anti-GFP and anti-GIP antibodies, respectively, in the upper small intestine of wild-type and GIP-GFP heterozygous and homozygous mice (Fig. 1D). GFP-expressing cells are present in the intestine of GIP-GFP heterozygous and homozygous mice and GIP-expressing cells are present in the intestine of both wild-type and GIP-GFP heterozygous mice. However, in GIP-GFP homozygous mice, no GIP-expressing cells were found. The GFP-expressing cells were identical to the GIP-expressing cells in the GIP-GFP heterozygous mice. We then examined the fasting plasma GIP levels in the three types of mice (Fig. 1E). GIP levels were significantly lower in GFP-GFP heterozygous mice compared with those in wild-type mice. GIP levels of GIP-GFP homozygous mice were not detectable. These results indicate that GIP-GFP heterozygous mice have only one normal gip gene and that GIP-GFP homozygous mice have no normal gip genes.

Next, GFP-positive cells were purified by a flow cytometry system. GFP-positive cells and GFP-negative cells from upper small intestinal epithelium of GIP-GFP heterozygous mice were separated and collected. GFP mRNA and GIP mRNA were highly expressed in GFP-positive cells (Fig. 1F). In microarray analysis, the expression levels of GIP mRNA were much higher in GFP-positive cells than those in GFP-negative cells (GFP-positive cells (n = 5–6) 12,951.55 versus GFP-negative cells (n = 5–6), *p = 0.05; **p = 0.01; ***p = 0.001). These results demonstrate that the GFP-positive cells in the intestinal epithelium of GIP-GFP mice are K-cells.

Rfx6 Increases GIP mRNA Expression in K-cells

Transcription Factor Rfx6 Is Expressed Exclusively in K-cells—Microarray analysis data revealed that mRNA of the transcription factor Rfx6 is highly expressed in GFP-positive cells (GFP-positive cells (n = 3) 12,951.55 ± 335.77 versus GFP-negative cells (n = 3) 1763.61 ± 142.65; p ≤ 0.001). These results demonstrate that the GFP-positive cells in the intestinal epithelium of GIP-GFP mice are K-cells.
of these mRNAs in mouse islets, GFP-positive cells (K-cells), and mouse small intestinal cell line STC-1 (Fig. 2A). All of the rfx genes, except for rfx4, were expressed in islets as shown in a previous study (20). Rfx3, Rfx6, and Rfx7 were expressed in GFP-positive cells, but no Rfx mRNAs were detected in the GFP-negative cells. In semi-quantitative RT-PCR data, the expression levels of Rfx6 were extremely higher in GFP-positive cells than those in GFP-negative cells, whereas the expression levels of Rfx3 and Rfx7 were similar (Fig. 2B). Immunohistochemistry confirmed that Rfx6-expressing cells correspond to GFP-expressing cells (Fig. 2C), demonstrating that Rfx6 is expressed exclusively in K-cells.

Inhibition of Rfx6 and Pdx1 Expression Decreases GIP Expression in STC-1 Cells—We then assessed the influence of Rfx6 on GIP expression and secretion by using STC-1 cells. Rfx6 mRNA expression was confirmed in STC-1 cells by RT-PCR (Fig. 2A). The Rfx6-expressing cells were similarly located in the GIP-expressing cells by immunohistochemistry (Fig. 2D). By treatment with Rfx6 siRNA, Rfx6 mRNA expression was inhibited by 70% (Fig. 2E). In the same condition, mRNA expression, cellular content, and secretion of GIP were significantly decreased whereas those of GLP-1 were similar to control (Fig. 2, E–G), indicating that Rfx6 increases GIP mRNA expression, cellular content, and secretion. However, Pdx1 is reported to be an important transcriptional factor for producing GIP in K-cells (17, 18), although its expression levels were similar in GFP-positive and GFP-negative cells (Fig. 3A). To examine the effect of Pdx1 on incretin expression and secretion, mRNA expression, cellular content, and secretion of GIP and GLP-1 were measured in Pdx1-knockdown STC-1 cells by using siRNA. Pdx1 mRNA expression was confirmed in STC-1 cells by RT-PCR (Fig. 3B). The expression levels of Pdx1 mRNA were decreased by 50% in STC-1 cells treated with Pdx1 siRNA (Fig. 3C). GIP mRNA expression, cellular content, and secretion were significantly decreased, whereas GLP-1 mRNA expression, cellular content, and secretion were somewhat increased in STC-1 cells treated with Pdx1 siRNA (Fig. 3, C–E). The expression levels of Rfx6 mRNA were significantly decreased in the cells (Fig. 3C).
Interaction of Rfx6 and GIP Gene—We assessed the interaction of the Rfx6 and gip gene by one-hybrid assay. Four fragments of the gip promoter were constructed (Fig. 4A). Rfx6 effectively bound to fragment b (5216–6512 base pairs (bp) upstream of the gip promoter) (Fig. 4B). In the luciferase reporter assay, gip promoter activity of fragments A and B containing 5216–6512 bp upstream of gip promoter was high, whereas the activities of gip promoter C, D, and E were significantly decreased (Fig. 4D). These results suggest that Rfx6 binds to the region 5216–6512 bp upstream of the gip promoter.

**FIGURE 3.** Effect of Pdx1 on mRNA expression, cellular content, and secretion of GIP. A, Pdx1 mRNA levels in GFP-positive cells and GFP-negative cells (n = 8–10). B, GIP, GLP-1, and Pdx1 mRNA expressions in STC-1 cells by RT-PCR. C, Pdx1, GIP, GLP-1, and Rfx6 mRNA levels in Pdx1 knockdown STC-1 cells (n = 4). D and E, incretin content and secretion in Pdx1 knockdown STC-1 cells (n = 4). *, p ≤ 0.05; **, p ≤ 0.01; ***, p < 0.001, n.s., not significant.

**FIGURE 4.** Interaction of Rfx6 and gip gene. A, design of the gip promoter fragments for one-hybrid assay. Numbers indicate nucleotides upstream from the transcription start site of the gip gene. B, results of yeast one-hybrid assay. Only yeast transformed with both pAbAi vector containing fragment b (pAbAi-fragment b) and Rfx6 cDNA-inserted pGADT7 (pGADT7-Rfx6) was grown on SD medium. C, design of the different lengths of gip promoter genes for luciferase reporter plasmid transfected in STC-1 cells. D, luciferase reporter assay on gip promoter. Data are represented by ratio of relative light units (RLU) of fragment E (n = 3–4). *, p ≤ 0.05, n.s., not significant. E and F, Pdx1, Rfx6, GIP, and GLP-1 mRNA levels in Rfx6-overexpressing STC-1 cells. **, p ≤ 0.01; ***, p ≤ 0.001 versus control, n.s., not significant.
Rfx6 Increases GIP mRNA Expression in K-cells

which regulates the gip promoter activity. Furthermore, Rfx6 was overexpressed in STC-1 cells by transfection of Rfx6 expression plasmids. The expression levels of Rfx6 mRNA levels were significantly higher in Rfx6-overexpressing cells compared with control (Fig. 4E). Rfx6 had no effect on the expression levels of Pdx1 mRNA. GIP mRNA expression levels were significantly increased in Rfx6-overexpressing cells, but GLP-1 mRNA expression levels were not (Fig. 4F).

HFD Feeding Increases GIP Secretion and Induces Obesity and Insulin Hypersecretion in GIP-GFP Heterozygous Mice—To investigate the mechanisms of GIP hypersecretion in HFD-induced obesity in vivo, GIP-GFP heterozygous mice were fed CFD or HFD for 8 weeks. One week after starting these diets, the body weight of the HFD group was significantly increased compared with that of the CFD group (Fig. 5A). There was no difference in food and water intake between the CFD and HFD groups (data not shown). After CHD or HFD feeding for 8 weeks, OGTTs were performed. Blood glucose levels were significantly increased at 60 and 120 min during OGTT in HFD group (Fig. 5B). Insulin levels also were significantly increased in the HFD group (Fig. 5C). Insulin secretion (area under the curve-insulin) of the HFD group was increased about 5.5-fold compared with that of the CFD group (CFD group (n = 6) 211,835 ± 456; p ≤
Rfx6 Increases GIP mRNA Expression in K-cells

0.001). GIP concentrations of HFD group at 15, 30, and 60 min were increased significantly compared with those of the CFD group (Fig. 5D). GIP secretion (area under the curve-GIP) of the HFD group was increased about 1.5-fold compared with that of the CFD group (CFD group (n = 6) 7368 ± 123 versus HFD group (n = 6) 10,531 ± 216; p ≤ 0.05) These results show that HFD feeding increases GIP secretion and induces obesity and insulin hypersecretion in GIP-GFP heterozygous mice, which have only one normal gip gene. GIP Hypersecretion in HFD-induced Obese Mice Is Not Due to Increase of K-cell Number but to Increase of GIP Expression in K-cells—To determine whether GIP hypersecretion involves an increased number of K-cells in HFD-fed GIP-GFP heterozygous mice, the number and localization of the K-cells in the upper small intestine were estimated and compared. The length of the mucous membrane and the number and localization of K-cells examined by immunohistochemistry were similar in the CFD and HFD group (Fig. 5, E–G). Flow cytometry analysis also showed no difference in K-cell number between the two groups (Fig. 5H). However, GIP content in the upper small intestine was significantly increased in the HFD group compared with that in the CFD group (Fig. 5I). In addition, in K-cells purified using flow cytometry, the expression levels of GIP mRNA were almost 10-fold higher in the HFD group than those in the CFD group (Fig. 5J). These results demonstrate that GIP hypersecretion under HFD-induced obesity is not due to an increase in K-cell number but to an increase of GIP mRNA expression and content in K-cells. Rfx6 and Pdx1 mRNA Levels Were Increased in K-cells of HFD-induced Obese Mice—We also assessed the expression of other candidate genes in K-cells (GFP-positive cells) (Fig. 5K) and non-K-cells (GFP-negative cells). Both Rfx6 and Pdx1 mRNA levels were increased in K-cells of the HFD group compared with those in K-cells of the CFD group, but the mRNA expression levels of Rfx3 and Rfx7 were not. Other Rfx transcriptional factors (Rfx1, -2, -4, and -5) were not detected in the K-cells of HFD-fed mice. Furthermore, none of the Rfx transcriptional factors were detected in non-K-cells. Pdx1 mRNA expression was detected in non-K-cells, but there was no significant difference in the expression level between the CHD group and the HFD group (ratio of Pdx1 mRNA to GAPDH mRNA: CFD group (n = 8) 0.47 ± 0.15 versus HFD group (n = 8) 0.26 ± 0.08; p = 0.24). These results strongly suggest that an increase in Rfx6 expression as well as Pdx1 expression in K-cells stimulates GIP mRNA expression and content in K-cells of HFD-fed obese mice.

DISCUSSION

Analysis of K-cells in vivo has been impossible due to the inability to isolate the GIP-producing K-cells from intestinal epithelium. In this study, GIP-GFP mice enabled sorting GFP-positive cells as K-cells and revealed that the transcription factor Rfx6 is expressed exclusively in K-cells by microarray analysis and RT-PCR (Fig. 2B). Rfx3 and Rfx7 also were detected in K-cells by RT-PCR, but there were no significant differences in their expression between K-cells and non-K-cells (Fig. 2B). The rfx gene family of transcription factors was first detected in mammals as regulatory factors that bind to the promoter regions of major histocompatibility complex (MHC) class II genes (21); seven types of Rfx (Rfx1–7) have so far been identified. All Rfx transcription factors have a winged helix DNA binding domain. Rfx1–4 and -6 have a dimerization domain (22, 23), and Rfx6 forms homodimers or heterodimers with Rfx2 or Rfx3 (24, 25). Rfx6 was initially isolated from human genome sequences in 2008 (22). Serial Analysis of Gene Expression (SAGE) frequency data showed high expression of Rfx6 mRNA in the pancreas, liver, and heart, and RT-PCR analysis showed high expression of Rfx6 mRNA in human pancreas and intestine (20). However, it is known that Rfx3 mRNA is expressed in brain, placenta, pancreas, and pituitary and that Rfx3 directly regulates the promoters of glut2 and glucokinase in pancreatic β-cells (26). Rfx7 is known to be expressed in many different tissues. rfx3- and rfx6-deficient mice were generated previously, and none of the endocrine cells, excluding pancreatic polypeptide-expressing cells, are detected in the islets of these mice (20, 27). These results suggest that Rfx3 and Rfx6 play a critical role in generating the endocrine cells in islets, but it is unknown whether they are associated with generation of enteroeendocrine cells such as K-cells and L-cells. We examined incretin mRNA expression and content under the inhibition of Rfx6 expression in STC-1 cells. Other incretin GLP-1 mRNA expression and content were preserved in Rfx6-knockdown STC-1 cells. However, GIP mRNA expression and content were significantly decreased in the cells (Fig. 2, E–G). In addition, Rfx3 expression tended to be higher in GFP-positive cells than that in GFP-negative cells (Fig. 2B), but GIP mRNA expression, content, and secretion were not changed in Rfx3-knockdown STC-1 cells (data not shown). These results suggest that Rfx6 expressed exclusively in K-cells plays an important role in GIP expression, cellular content, and secretion in K-cells. In addition, we examined the effect of Rfx6 on the gip gene and found that Rfx6 binds to the region 5216–6512 bp upstream of the gip promoter gene (Fig. 4D) and that Rfx6 increased GIP mRNA expression in STC-1 cells (Fig. 4F). Further study is needed to clarify the regulatory mechanism of gip promoter activity by Rfx6. In previous studies, characterization of K-cells and microarray analysis were done using purified K-cells from the intestine of transgenic mice expressing a yellow fluorescent protein (YFP) under the control of the 200-kb rat gip promoter (28, 29), but Rfx6 expression in K-cells was not reported. The reason such a long promoter is required for specific expression of YFP in K-cells is not known, but it suggests that regulation of gip gene expression is under complex control. In this study, we established GIP-GFP mice in which GFP is under an endogenous native promoter. Using these GIP-GFP mice, we were able to determine that Rfx6 is expressed exclusively in K-cells. In previous studies, Pdx1 expression was detected in K-cells, and pdx1-deficient mice showed a greatly decreased number of GIP-expressing cells in the intestine (18, 19). It has also been reported that Pdx1 binds 150 bp upstream of the gip promoter, activates the gip promoter in STC-1 cells, and that Pdx1 expression is essential for producing GIP in K-cells (18, 19). We found that there was no significant difference in Pdx1 mRNA expression between upper small intestinal K-cells and non-K-cells (Fig. 3A). These findings suggest the possibility that Rfx6 spe-
specifically expressed in K-cells plays a critical role in differentiation and GIP production of K-cells in collaboration with Pdx1. It was reported that Rfx6 mRNA expression is regulated by transcription factor neurogenin 3 (Ngn3) in the pancreas of the mouse fetus (30). In another report, no colocalization of Pdx1-expressing cells and Rfx6-expressing cells was found in pancreas of the mouse fetus using immunohistochemistry analysis, and Pdx-1 expression was decreased in the pancreas of Rfx6-deficient mice (20). In this study, Pdx1 mRNA expression levels were changed not only in Rfx6-knockdown STC-1 cells but also in Rfx6-overexpressing STC-1 cells, whereas Rfx6 expression levels were significantly decreased in Pdx1 knockdown STC-1 cells (Figs. 2E, 3C, and 4E). These results suggest that Rfx6 expression is regulated at least in part by Pdx1.

Increased blood GIP levels in obesity have been reported in several studies (7, 14–16). There is a report that healthy human subjects administered high fat food for 2 weeks showed increased plasma GIP levels without developing obesity, suggesting that GIP hypersecretion precedes obesity (31). GIP is released from K-cells into the circulation in response to various nutrients (32–34). Measurement of total GIP and total GLP-1 levels in humans challenged with glucose or meal shows that the postprandial plasma GIP level is greatly augmented when a meal containing abundant fat rather than simple glucose is consumed (35, 36). This suggests that intake of HFD increases GIP secretion and strengthens both direct and indirect effects of GIP on energy accumulation in adipose tissue. We previously reported that both GIP levels after glucose loading and body mass index have a positive correlation in healthy subjects (37). In this study, GIP levels during OGTT were increased in obese GIP-GFP heterozygous mice compared with those in lean GIP-GFP heterozygous mice, even though GIP-GFP heterozygous mice have only one normal *gip* gene, indicating these mice represent a useful model for analysis of the mechanisms involved in the augmented GIP secretion in HFD-induced obesity. A previous study reported that augmentation of GIP secretion in HFD feeding conditions is due to increased K-cell number (38). In that report, agglomerates of Pdx1 and GIP double-expressing cells were found inside the duodenal mucosa of obese rats after HFD feeding. In this study, however, we could not detect agglomerates of K-cells or an increase of K-cell number in the duodenum or upper small intestine of HFD-induced obese mice, which suggests that induction of Rfx6 as well as Pdx1 plays a critical role in GIP hypersecretion in HFD-induced obesity.

In conclusion, gene analysis of K-cells isolated from GIP-GFP mice enables identification of the transcription factor Rfx6 that is expressed exclusively in K-cells and is involved in the regulation of GIP expression. We also show that expression of Rfx6 and Pdx1 is up-regulated in the K-cells of HFD-induced obese mice, which suggests that induction of Rfx6 as well as Pdx1 plays a critical role in GIP hypersecretion in HFD-induced obesity.

Acknowledgments—We thank Prof. Douglas Hanahan, University of California, San Francisco, for kindly providing the STC-1 cells. We also thank Dr. Yoshitaka Hayashi, Research Institute of Environmental Medicine, Nagoya University, for helpful suggestions regarding the study. Mouse anti-GIP antibody was kindly provided by Merck Millipore.

REFERENCES

1. Reaven, G. M. (1988) Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 37, 1595–1607
2. Kahn, B. B., and Flier, J. S. (2000) Obesity and insulin resistance. *J. Clin. Invest.* 106, 473–481
3. Lemieux, I., Pascot, A., Couillard, C., Larbarche, B., Tcherenoff, A., Almás, N., Bergeron, J., Gaudet, D., Tremblay, G., Prud’homme, D., Nadeau, A., and Després, J. P. (2000) Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinaemia; hyperapolipoprotein B; small, dense LDL) in men. *Circulation* 102, 179–184
4. Pederson, R. A. (1994) In Gut Peptides: Biochemistry and Physiology (Walsh, J. H., and Dockray, G. J., eds) pp. 217–259, Raven Press, New York
5. Drucker, D. J. (1998) Glucagon-like peptides. *Diabetes* 47, 159–169
6. Seino, Y., Fukushima, M., and Yabe, D. (2010) GIP and GLP-1, the two incretin hormones. Similarities and differences. *J. Diabetes Invest.* 1, 8–23
7. Miyawaki, K., Yamada, Y., Ban, N., Ibara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oka, A., Tsuda, K., Toyokuni, S., Hiai, M., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsabamoto, Y., Iinouchi, T., Jomori, T., and Seino, Y. (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. *Nat. Med.* 8, 738–742
8. Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Beshko, K., Li, M., Amizuka, N., Sato, M., Udagawa, N., Takahashi, N., Tanaka, K., Oiso, Y., and Seino, Y. (2006) Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation following food ingestion. *Mol. Endocrinol.* 20, 1644–1651
9. Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ibara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., Tsuda, K., Hashimoto, H., Yamashita, T., Jomori, T., Tashiro, F., Miyazaki, I., and Seino, Y. (1999) Glucose intolerance caused by a defect in the entero-insular axis. A study in gastric inhibitory polypeptide receptor knockout mice. *Proc. Natl. Acad. Sci. U.S.A.* 96, 14843–14847
10. Harada, N., Yamada, Y., Tsukiyama, K., Yamada, C., Nakamura, Y., Mukai, E., Hamasaki, A., Liu, X., Toyoda, K., Seino, Y., and Inagaki, N. (2008) A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice. *Ann. J. Physiol. Endocrinol. Metab.* 294, E61–E68
11. Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., and Bonner, T. I. (1993) Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal polypeptide receptor family, is widely distributed in peripheral organs and the brain. *Endocrinology* 133, 2861–2870
12. Hauner, H., Glattling, G., Kaminska, D., and Pfeiffer, E. F. (1988) Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. *Ann. Nutr. Metab.* 32, 282–288
13. Song, D. H., Getty-Kaushik, L., Tseng, E., Simon, J., Corkey, B. E., and Wolfe, M. M. (2007) Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. *Gastroenterology* 133, 1796–1805
14. Bailey, C. J., Platt, P. R., Kwasowski, P., Powell, C. J., and Marks, V. (1986) Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in
obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. *Acta Endocrinol.* **112**, 224–229

15. Flatt, P. R., Bailey, C. J., Kwasiowski, P., Swanston-Flatt, S. K., and Marks, V. (1983) Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. *Diabetes* **32**, 433–435

16. Creutzfeldt, W., Ebert, R., Willms, B., Frerichs, H., and Brown, J. C. (1978) Gastric inhibitory polypeptide (GIP) and insulin in obesity. Increased response to stimulation and defective feedback control of serum levels. *Diabetologia* **14**, 15–24

17. Jonsson, I., Carlsson, L., Edlund, T., and Edlund, H. (1994) Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* **371**, 606–609

18. Jepeal, L. I., Fujitani, Y., Boylan, M. O., Wilson, C. N., Wright, C. V., and Reith, W. (1998) Identification and characterization of novel human tissue-specific RFX transcription factors. *Proc. Natl. Acad. Sci. U.S.A.* **86**, 4200–4204

19. Fujita, Y., Chui, J. W., King, D. S., Zhang, T., Seufert, J., Pownall, S., Mach, B. (1989) Cloning of the major histocompatibility complex class II promoter binding protein affected heredity defect in class II gene regulation. *Proc. Natl. Acad. Sci. U.S.A.* **86**, 4200–4204

20. Aftab, S., Semenec, L., Chu, J. S., and Chen, N. (2008) Identification and characterization of novel human tissue-specific RFX transcription factors. *BMC Evol. Biol.* **8**, 226–236

21. Reith, W., Barras, E., Satola, S., Kohr, M., Reinhart, D., Sanchez, C. H., and Mach, B. (1989) Cloning of the major histocompatibility complex class II promoter binding protein affected heredity defect in class II gene regulation. *Proc. Natl. Acad. Sci. U.S.A.* **86**, 4200–4204

22. Smith, S. B., Hu, H. Q., Taleb, N., Kishimoto, N. Y., Scheel, D. W., Lu, Y., Patch, A. M., Grabs, R., Wang, J., Lynn, F. C., Miyatsuka, T., Mitchell, J., Seerke, R., Desir, J., Vanden Eijnden, S., Abramowicz, M., Kacet, N., Weill, J., Renard, M. E., Gentile, M., Hansen, I., Dewar, K., Hattersley, A. T., Wang, R., Wilson, M. E., Johnson, J. D., Polychronakos, C., and German, M. S. (2010) Rfx6 direct islet formation and insulin production in mice and humans. *Nature* **463**, 775–780

23. Ait-Lounis, A., Baas, D., Barras, E., Benadiba, C., Charollais, A., Nlend Nlend, R., Liègeois, D., Meda, P., Durand, B., and Reith, W. (2007) Novel function of ciliogenic transcription factor RFX in development of the endocrine pancreas. *Diabetes* **56**, 950–959

24. Pancreatic islet development. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 1233–1238

25. Farrell, M., O’Dwyer, T., O’Neill, P. J., and O’Leary, D. (2009) Increased GIP mRNA expression in K-cells. *J. Diabetes Invest.* **2**, 951–959

26. Jansen, K., Delahunty, C., D’Souza, S., and Wollheim, C. A. (2009) Identification and characterization of novel human tissue-specific RFX transcription factors. *BMC Evol. Biol.* **8**, 226–236

27. Falko, J. M., Crockett, S. E., Cataland, S., and Mazzaferri, E. L. (1975) Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. *Diabetes* **24**, 4200–4204

28. Wolfs, A., Berriz, G. F., Gibbons, F. D., Dreze, M., Ayivi-Guedehoussou, N., Klitgaard, N., Berriz, G. F., Gibbons, F. D., Dreze, M., Ayivi-Guedehoussou, N., Klitgaard, N., Simon, C., Boxem, M., Milstein, S., Rosenberg, J., Goldberg, D. S., Ebert, R., Willms, B., Frerichs, H., and Brown, J. C. (1978) Gastric inhibitory polypeptide (GIP) and insulin in obesity. Increased response to stimulation and defective feedback control of serum levels. *Diabetologia* **14**, 15–24

29. Habib, A. M., Richards, P., Cairns, L. S., Rogers, G. J., Bannon, C. A., Parker, H. E., Morley, T. C., Yeo, G. S., Reimann, F., and Gribble, F. M. (2012) Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. *Endocrinology* **153**, 3054–3065

30. D’Souza, S., and Wollheim, C. A. (2009) Identification and characterization of novel human tissue-specific RFX transcription factors. *BMC Evol. Biol.* **8**, 226–236

31. Soyer, J., Flaske, L., Raffelsberger, W., Beucher, A., Orvain, C., Peers, B., Ravassard, P., Vermot, J., Voz, M. L., Mellitzer, G., and Gradwohl, G. (2010) Rfx6 is an Ngn3-dependent winged helix transcription factor required for pancreatic islet cell development. *Development* **137**, 203–212

32. Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., and Inagaki, N. (2012) Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. *Endocrinology* **153**, 3054–3065

33. Habib, A. M., Richards, P., Cairns, L. S., Rogers, G. J., Bannon, C. A., Parker, H. E., Morley, T. C., Yeo, G. S., Reimann, F., and Gribble, F. M. (2012) Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. *Endocrinology* **153**, 3054–3065

34. Sjolander, K., H cycling to glucose, insulin, and glucokinase expression. *Nature* **463**, 1173–1178

35. Vollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E, and Meier, J. J. (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. *Diabetes* **57**, 678–687

36. Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., and Inagaki, N. (2012) Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. *Endocrinology* **153**, 3054–3065

37. Harada, N., Hamasaki, A., Muraoka, A., Joo, E., Suzuki, K., Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., and Inagaki, N. (2012) Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. *Diabetes* **56**, 1674–1685

38. Yamane, S., Harada, N., Hamasaki, A., Muraoka, A., Joo, E., Suzuki, K., Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., and Inagaki, N. (2012) Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. *Diabetes* **56**, 1674–1685

39. Yoder, S. M., Yang, Q., Kindel, T. L., and Tso, P. (2010) Differential responses of the incretin hormones GIP and GLP-1 to increasing doses of dietary carbohydrate but not dietary protein in lean rats. *Am. J. Physiol. Gastrointest. Liver Physiol.* **299**, G476–G485

40. Brown, J. C., Dryburgh, J. L., Ross, S. A., and Dupré, J. (1975) Identification and actions of gastric inhibitory polypeptide. *Recent Prog. Horm. Res.* **31**, 487–532

41. Falko, J. M., Crockett, S. E., Cataland, S., and Mazzaferrli, E. L. (1975) Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. *J. Clin. Endocrinol. Metab.* **41**, 260–265

42. Vollmer, K., Holst, J. J., Baller, B., Ehrlichmann, M., Nauck, M. A., Schmidt, W. E, and Meier, J. J. (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. *Diabetes* **57**, 678–687

43. Yamane, S., Harada, N., Hamasaki, A., Muraoka, A., Joo, E., Suzuki, K., Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., and Inagaki, N. (2012) Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. *Diabetes* **53**, 193–199

44. Gniul, D., CalTag, A., Dalla Libera, L., Calvani, R., Leccesi, L., Caristo, M. E., Vettor, R., Castagneto, M., Ghirlanda, G., and Mingrone, G. (2010) High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. *Diabetologia* **53**, 2233–2240